EVOTEC SE INH O.N.
Commented by André Will-Laudien on November 6th, 2025 | 07:10 CET
Novo Nordisk calculating carefully, Evotec facing potential takeover? Clinical trial and up-listing at Vidac!
The stock market is showing some turbulence in the biotech sector. Unlike the big growth stocks on the NASDAQ, there is still urgent catching-up to do here. Some figures, such as those from Novo Nordisk and Evotec, still give reason for concern. The situation is quite different at Vidac Pharma, where an up-listing to the primary market is on the horizon and a clinical trial is about to begin! Plenty of material for investors' dreams to grow. We calculate where an investment is worthwhile!
Read
Commented by Fabian Lorenz on November 5th, 2025 | 07:10 CET
Millions for BioNTech and Evotec! But drug development is costly! Is NetraMark the next takeover target?
NetraMark scores again. The Company's AI has convinced yet another biopharma company and is increasingly shaping up as a potential takeover target. The new client will use NetraAI to optimize its clinical trial, cutting both time and costs. The high expense of drug development is clear: BioNTech invested EUR 565 million into its pipeline last quarter. However, the German biotech leader can afford this thanks to billions in its coffers. Analysts still recommend buying the stock. By contrast, even a million-dollar payment from a partner could not give Evotec shares any real momentum. Could today’s figures finally spark a turnaround?
Read
Commented by Fabian Lorenz on October 17th, 2025 | 07:15 CEST
Acquisition of Vidac Pharma and Evotec? USD 400 billion at stake for Pfizer, Merck & Co!
Alarm bells are ringing in Big Pharma! Donald Trump appears serious about reducing drug prices. At the same time, patents on blockbuster drugs are expiring, threatening a USD 400 billion revenue shortfall. Pfizer, Merck, and Co. must refill their pipelines. The acquisition merry-go-round is expected to spin even faster in the coming years. Among the potential takeover targets is Vidac Pharma. The Company is still attractively priced, but if its new approach to fighting cancer proves successful in early clinical trials, a multiplication could be possible. And what about Evotec? The Hamburg-based company has repeatedly been traded as a takeover candidate in recent years. However, data and patents are offset by internal problems.
Read
Commented by Fabian Lorenz on October 14th, 2025 | 07:30 CEST
Alternative to BioNTech, Evotec, and Co.: BioNxt Solutions impresses at investor conference and sparks takeover speculation
While the shares of BioNTech and Evotec are treading water, BioNxt Solutions is on an upward trajectory. The Company is currently shaking up Big Pharma. The announcement to replace the weight-loss injection Ozempic with an oral dissolvable film has sparked takeover speculation. BioNxt also aims to make waves in multiple sclerosis, another multi-billion-dollar market, by significantly simplifying the administration of a blockbuster drug for patients. At last week's IIF investor conference, the management board delivered a convincing presentation. Partnerships and licensing opportunities were outlined - assuming no acquisition occurs beforehand. This could prove highly rewarding for both a pharmaceutical company and shareholders.
Read
Commented by Armin Schulz on October 9th, 2025 | 07:40 CEST
AI paves the way to the next blockbuster: The current situation at Novo Nordisk, NetraMark Holdings and Evotec
The pharmaceutical industry is at a historic turning point. Artificial intelligence is breaking through the lengthy and costly development cycles that have characterized the sector for decades. This technological quantum leap is revolutionizing drug discovery and promises to transform healthcare from the ground up. The first companies to master this AI revolution will be the biggest winners in a billion-dollar market. We therefore take a look at three companies that are already using AI today: the Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings for clinical studies, and the German research service provider Evotec, and analyze their current situation.
Read
Commented by Carsten Mainitz on October 9th, 2025 | 07:35 CEST
BioNxt Solutions, Bayer, Evotec – Enormous upside! The interface of biotech and pharmaceuticals!
The global rise in lifestyle diseases such as diabetes, obesity, multiple sclerosis (MS), and MASH (metabolic fatty liver disease) is driving enormous growth in the healthcare sector. The market for cancer therapies is also expanding rapidly. Meanwhile, the M&A landscape is developing dynamically: large pharmaceutical companies need to act as patent protections expire, securing their pipeline through acquisitions and partnerships. Areas offering innovative drugs or novel delivery methods are especially attractive. This is where a promising second-tier stock comes into play.
Read
Commented by Carsten Mainitz on October 2nd, 2025 | 07:10 CEST
NetraMark Holdings, Evotec, Sartorius – Billion-dollar deals in sight!
Artificial intelligence and machine learning have become key drivers across nearly every industry. When pharmaceutical companies successfully develop a drug to market readiness, profits can surge. However, only a few active ingredients that enter clinical trials ultimately receive approval. It is therefore a long, risky, and costly process. The use of AI can help to minimize these risks significantly. Here, we take a look at the potential of AI-based strategies among established players Evotec and Sartorius, with a particular focus on the innovative approach of Canadian company NetraMark Holdings.
Read
Commented by André Will-Laudien on September 29th, 2025 | 07:20 CEST
Attention: Acquisitions! Biotechs like Evotec, PanGenomic Health, Pfizer, and BioNTech in focus
The biotech industry is in turmoil! With the expiration of blockbuster patents, there is a threat of sharp declines in revenue, which must be strategically compensated for. Driven by economic pressure and a growing focus on innovation and technology, the industry is increasingly turning to acquisitions of biotech companies with promising drug candidates, new technologies, and digital expertise. Not only are entire pipelines being acquired, but key players from the fastest-growing segments are also being targeted, particularly in the field of obesity therapies, where billions are being paid for drug candidates. Several examples illustrate this wave of transformation. Companies are restructuring, focusing their activities, and rapidly preparing for a phase of sustainable growth. The pace is picking up! Here are some promising investment ideas!
Read
Commented by Carsten Mainitz on September 22nd, 2025 | 07:55 CEST
AJN Resources, TUI, Evotec: Fresh capital and insider purchases!
Fresh capital, insider purchases, or significant changes in the shareholder base can be important signals regarding future share price performance. The leverage effect of fresh capital is particularly high for smaller companies. This is because projects can be launched with manageable amounts of capital, bringing important milestones closer. However, the stock market sometimes reacts late because small or micro-caps fly under the radar of the investor community. However, it is precisely this constellation that creates good opportunities for active and vigilant investors.
Read
Commented by Fabian Lorenz on September 18th, 2025 | 07:25 CEST
Adidas to take over Puma? Evotec with insider buying! 50% upside potential with AI stock NetraMark!
Adidas and Puma caught in merger fever? A US investor brings the spectacular idea into play. Is it a means of exerting pressure on Puma's management or a real possibility? What do analysts say? Meanwhile, Evotec is sending a signal of confidence with fresh insider purchases. However, the stock is still digesting the recent revenue forecast downgrade. Could there be fresh momentum next week? In contrast, NetraMark shares offer a 50% return. For this to happen, however, the AI-driven drug development specialist must reach the analysts' price target. Operationally, there is much to be said for this, and in comparative tests, the Company has outperformed ChatGPT and DeepSeek.
Read